Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director | June 12, 2026 | June 15, 2026 |
| Shattuck Labs, Inc.STTK · Entity 5224 | Director | July 14, 2025 | July 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2036-06-12 | Direct | 87,900 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 87,900 · Balance 87,900 F1: The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2: The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3: The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date.
F2: The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F4: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
Shattuck Labs, Inc.
Report date July 14, 2025 · Filed July 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2035-07-14 | Direct | 33,150 |
Reported balance
After 2025-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-14 · Grant · Acquired 33,150 · Balance 33,150 F1: This option represents a right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date. F2: The stock option was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date.
F2: The stock option was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IGM Biosciences, Inc.
Report date August 14, 2025 · Filed August 14, 2025
Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-14 · Disposition to issuer · Disposed 12,712 · Balance 0 F1: On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger, dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement . The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). F2: The reported securities were granted to Michael Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee held these securities as a nominee on behalf, and for the sole benefit, of Redmile and assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaimed beneficial ownership of the reported securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger, dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement . The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing").
F2: The reported securities were granted to Michael Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee held these securities as a nominee on behalf, and for the sole benefit, of Redmile and assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaimed beneficial ownership of the reported securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:15 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 87,900 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001104659-26-074126 · tm2617974-1_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,900 Underlying: Common Stock · 87,900 shares Expires 2036-06-12 F1 · derivative.exercise_date: The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 19:35 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerCommon Stock | 12,712 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-078832 · tm2523477-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger, dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement . The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). F1 · price: On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger, dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement . The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). F2 · ownership.direct: The reported securities were granted to Michael Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee held these securities as a nominee on behalf, and for the sole benefit, of Redmile and assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaimed beneficial ownership of the reported securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 14, 2025 Filed Jul 17, 2025 01:01 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 33,150 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001104659-25-068454 · tm2521022-2_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires 2035-07-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date. F2 · ownership.direct: The stock option was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:02 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 828 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065262 · tm2519690-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,712 F1 · shares: These securities are fully vested restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:55 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001104659-25-055046 · tm2516695-2_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: The stock option will vest in full and become exercisable upon the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:01 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 828 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031355 · tm2511107-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,884 F1 · shares: These securities are fully vested restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 21:02 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000434 · tm2432282-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,056 F1 · shares: These securities are fully vested restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:15 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-105558 · tm2425347-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,322 F1 · shares: These securities are fully vested restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 21:30 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-077492 · tm2418671-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,588 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 23:24 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 27,700 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001104659-24-074033 · tm2417794-2_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,700 Underlying: Common Stock · 27,700 shares Expires 2034-06-21 F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,700 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date. F2 · ownership.direct: The stock option was granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 22:20 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001104659-24-070507 · tm2416874-2_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-07 F1 · derivative.exercise_date: The stock option will vest in full and become exercisable upon the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 19:18 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-042722 · tm2410246-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,854 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 19:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (Right to Buy) · Derivative | 29,400 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001104659-24-034642 · tm248883-1_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2034-03-12 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month that is completed after the date of the Issuer's first annual stockholder meeting following the grant date of the options (the "Annual Meeting"), provided that the options will vest in full on the earlier of (i) the 12-month anniversary of the Annual Meeting, or (ii) the date of the Issuer's next annual stockholder meeting, in each case subject to Mr. Lee continuing to provide his service as a member of the Board of Directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 20:49 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001045 · tm241473-3_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,120 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-106523 · tm2327412-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,628 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:47 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077731 · tm2320479-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,136 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:22 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001104659-23-069538 · tm2318137-1_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The stock option will vest in full upon the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 26, 2023 Filed May 31, 2023 22:39 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 40,258 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001104659-23-066719 · tm2317377-1_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Common Stock · 40,258 shares Expires 2033-05-26 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,258 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:30 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (Right to Buy) · Derivative | 15,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001104659-23-042872 · tm2311991-1_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2033-04-04 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month that is completed after the date of the Issuer's first annual stockholder meeting following the grant date of the options (the "Annual Meeting"), provided that the options will vest in full on the earlier of (i) the 12-month anniversary of the Annual Meeting, or (ii) the date of the Issuer's next annual stockholder meeting, in each case subject to Mr. Lee continuing to provide his service as a member of the Board of Directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:30 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041781 · tm2311421-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,644 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:32 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001105 · tm231489-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,152 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:53 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-106086 · tm2227387d1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,922 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:45 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077498 · tm2220422-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,692 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 09, 2022 Filed Jun 14, 2022 01:30 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 11,893 | $0.00 Strike: $23.48 | $0.00 |
DisclosureSEC source: 0001104659-22-070679 · tm2218292-1_4seq1.xml · derivative · entry 2 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,893 Underlying: Common Stock · 11,893 shares Expires 2032-06-09 F5 · derivative.exercise_date: The stock option will vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The equity award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The equity award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 09, 2022 Filed Jun 14, 2022 01:30 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 8,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-070679 · tm2218292-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,331 F1 · shares: The reported securities are represented by restricted stock units, which will vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The equity award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The equity award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 01:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 40,258 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001104659-22-070287 · tm2218131-1_4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,258 Underlying: Common Stock · 40,258 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,258 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:46 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042453 · tm2211545-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,462 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 21:46 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (Right to Buy) · Derivative | 29,497 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001104659-22-034128 · tm229399-2_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,497 Underlying: Common Stock · 29,497 shares Expires 2032-03-12 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the Issuer's 2022 Annual Meeting of Stockholders on the same day of the month, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date; provided, however, if the Issuer's 2023 Annual Meeting of Stockholders is prior to the one-year anniversary of the Issuer's 2022 Annual Meeting of Stockholders, then the shares subject to the option will be fully vested as of the date of the Issuer's 2023 Annual Meeting of Stockholders. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:46 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-001188 · tm221437d2_4.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:01 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-122675 · tm2129106-2_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:33 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-088919 · tm2121339d2_form4.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 19, 2021 Filed Jun 23, 2021 00:09 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 3,434 | $0.00 Strike: $29.34 | $0.00 |
DisclosureSEC source: 0001104659-21-084308 · tm2120423-2_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,434 Underlying: Common Stock · 3,434 shares Expires 2031-06-19 F1 · derivative.exercise_date: This option represents a right to purchase a total of 3,434 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 4,334 | $0.00 Strike: $68.94 | $0.00 |
DisclosureSEC source: 0001104659-21-077002 · tm2118520-1_4seq1.xml · derivative · entry 2 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,334 Underlying: Common Stock · 4,334 shares Expires 2031-06-02 F5 · derivative.exercise_date: The shares subject to the stock option will vest in full upon the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The equity award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The equity award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 2,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-077002 · tm2118520-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 F1 · shares: The reported securities are represented by restricted stock units, which will vest in full upon the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date. F2 · ownership.direct: The equity award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The equity award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 18:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046189 · tm2111935-1_4seq1.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (Right to Buy) · Derivative | 6,423 | $0.00 Strike: $91.50 | $0.00 |
DisclosureSEC source: 0001104659-21-026880 · tm217633-1_4seq1.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,423 Underlying: Common Stock · 6,423 shares Expires 2031-02-19 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the Issuer's 2021 Annual Meeting of Stockholders on the same day of the month, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date; provided, however, if the Issuer's 2022 Annual Meeting of Stockholders is prior to the one-year anniversary of the Issuer's 2021 Annual Meeting of Stockholders, then the shares subject to the option will be fully vested as of the date of the Issuer's 2022 Annual Meeting of Stockholders. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:14 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-001160 · tm211569-1_4.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile. Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:28 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 1,286 | $0.00 Strike: $53.02 | $0.00 |
DisclosureSEC source: 0001104659-20-139777 · tm2039412d2_4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286 Underlying: Common Stock · 1,286 shares Expires 2030-12-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 1,286 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:13 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-112193 · tm2032377d2_4.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 19:37 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-081464 · tm2024219d2_4.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:21 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $26.59 | $0.00 |
DisclosureSEC source: 0001104659-20-056896 · tm2018581d1_4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-01 F1 · derivative.exercise_date: The shares subject to the stock option will vest in full upon the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through each vesting date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:52 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 178 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-043316 · tm2014824d4_4.xml · nonDerivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178 F1 · shares: The reported securities are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects payment to Mr. Michael Lee of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. F2 · ownership.direct: The securities were granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 18:00 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $40.27 | $0.00 |
DisclosureSEC source: 0001104659-20-012640 · tm206948d1_4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the Issuer's 2020 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person's continued service to the Issuer through each applicable vesting date; provided, however, if the Issuer's 2021 Annual Meeting of Stockholders is prior to the one-year anniversary of the Issuer's 2020 Annual Meeting of Stockholders, then the shares subject to the option will be fully vested as of the date of the Issuer's 2021 Annual Meeting of Stockholders. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 16:37 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (Right to Buy) · Derivative | 12,100 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001144204-19-045264 · tv529725_4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,100 Underlying: Common Stock · 12,100 shares Expires 2029-09-17 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on September 17, 2020 and 1/36th of the shares subject to the option shall vest on each monthly anniversary thereafter, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0001144204-19-023893 · tv520715_4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-03 F1 · derivative.exercise_date: The shares subject to the stock option will vest in full upon the earlier of May 3, 2020 or the date of the following annual meeting of stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through each vesting date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his service as a member of the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 10:09 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001144204-18-041514 · tv499951_form4.xml · derivative · entry 1 Lee Michael Stewart · CIK 0001748010 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares subject to the stock option will vest in equal monthly installments during the 36 months following the grant date, subject to Michael Lee's continued service on the Board of Directors of the Issuer through each vesting date. F2 · ownership.direct: The stock option was granted to Mr. Lee in connection with his appointment to the Board of Directors of the Issuer. Mr. Lee, a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile Group, LLC ("Redmile"). Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F3 · ownership.direct: The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F4 · ownership.direct: Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.